Promising new agents in the prevention of transplant rejection.

C. Ponticelli, A. Tarantino

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Promising immunosuppressive drugs designed to prevent rejection have been developed recently. Two monoclonal antibodies directed against the interleukin-2 (IL-2) receptor, daclizumab and basiliximab, have been shown to significantly reduce the incidence of acute rejection without increasing adverse events. Sirolimus (rapamycin), an agent that inhibits T- and B-response at a later stage than cyclosporin, has been shown to be synergistic with cyclosporin in experimental and clinical studies. Ongoing clinical trials have reported that in renal transplantation high doses of sirolimus are as effective as cyclosporin. SDZ-RAD, a derivative of sirolimus, is also under investigation. FTY-720 another promising drug, prolonged the survival of allografts and synergised with cyclosporin and sirolimus in experimental models. Gusperimus (deoxyspergualin), which inhibits IL-1 synthesis, was useful in reversing early and late acute rejection in clinical trials. Antisense oligonucleotides which interfere with intercellular adhesion molecules which are important in rejection, gave encouraging results in primate renal allografts. The availability of these new drugs will be able to further abate the risk of rejection in organ transplantation. However, caution is warranted with their use in order to avoid the risks of over immunosuppression. Today excellent results can be obtained with the available drugs. Newer immunosuppressive schedules should be designed, not only to reduce the risk of rejection, but also to obtain a better therapeutic index that allows a further improvement of the graft survival while minimising the comorbidity and drug-related toxicity.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalDrugs in R and D
Volume1
Issue number1
Publication statusPublished - Jan 1999

Fingerprint

Graft Rejection
Sirolimus
Cyclosporine
Immunosuppressive Agents
Pharmaceutical Preparations
Allografts
Clinical Trials
Antisense Oligonucleotides
Interleukin-2 Receptors
Cell Adhesion Molecules
Organ Transplantation
Graft Survival
Drug-Related Side Effects and Adverse Reactions
Interleukin-1
Kidney Transplantation
Immunosuppression
Primates
Comorbidity
Appointments and Schedules
Theoretical Models

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ponticelli, C., & Tarantino, A. (1999). Promising new agents in the prevention of transplant rejection. Drugs in R and D, 1(1), 55-60.

Promising new agents in the prevention of transplant rejection. / Ponticelli, C.; Tarantino, A.

In: Drugs in R and D, Vol. 1, No. 1, 01.1999, p. 55-60.

Research output: Contribution to journalArticle

Ponticelli, C & Tarantino, A 1999, 'Promising new agents in the prevention of transplant rejection.', Drugs in R and D, vol. 1, no. 1, pp. 55-60.
Ponticelli, C. ; Tarantino, A. / Promising new agents in the prevention of transplant rejection. In: Drugs in R and D. 1999 ; Vol. 1, No. 1. pp. 55-60.
@article{8c8ffd4ffa4a48b988ab3a18d9740a7f,
title = "Promising new agents in the prevention of transplant rejection.",
abstract = "Promising immunosuppressive drugs designed to prevent rejection have been developed recently. Two monoclonal antibodies directed against the interleukin-2 (IL-2) receptor, daclizumab and basiliximab, have been shown to significantly reduce the incidence of acute rejection without increasing adverse events. Sirolimus (rapamycin), an agent that inhibits T- and B-response at a later stage than cyclosporin, has been shown to be synergistic with cyclosporin in experimental and clinical studies. Ongoing clinical trials have reported that in renal transplantation high doses of sirolimus are as effective as cyclosporin. SDZ-RAD, a derivative of sirolimus, is also under investigation. FTY-720 another promising drug, prolonged the survival of allografts and synergised with cyclosporin and sirolimus in experimental models. Gusperimus (deoxyspergualin), which inhibits IL-1 synthesis, was useful in reversing early and late acute rejection in clinical trials. Antisense oligonucleotides which interfere with intercellular adhesion molecules which are important in rejection, gave encouraging results in primate renal allografts. The availability of these new drugs will be able to further abate the risk of rejection in organ transplantation. However, caution is warranted with their use in order to avoid the risks of over immunosuppression. Today excellent results can be obtained with the available drugs. Newer immunosuppressive schedules should be designed, not only to reduce the risk of rejection, but also to obtain a better therapeutic index that allows a further improvement of the graft survival while minimising the comorbidity and drug-related toxicity.",
author = "C. Ponticelli and A. Tarantino",
year = "1999",
month = "1",
language = "English",
volume = "1",
pages = "55--60",
journal = "Drugs in R and D",
issn = "1174-5886",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Promising new agents in the prevention of transplant rejection.

AU - Ponticelli, C.

AU - Tarantino, A.

PY - 1999/1

Y1 - 1999/1

N2 - Promising immunosuppressive drugs designed to prevent rejection have been developed recently. Two monoclonal antibodies directed against the interleukin-2 (IL-2) receptor, daclizumab and basiliximab, have been shown to significantly reduce the incidence of acute rejection without increasing adverse events. Sirolimus (rapamycin), an agent that inhibits T- and B-response at a later stage than cyclosporin, has been shown to be synergistic with cyclosporin in experimental and clinical studies. Ongoing clinical trials have reported that in renal transplantation high doses of sirolimus are as effective as cyclosporin. SDZ-RAD, a derivative of sirolimus, is also under investigation. FTY-720 another promising drug, prolonged the survival of allografts and synergised with cyclosporin and sirolimus in experimental models. Gusperimus (deoxyspergualin), which inhibits IL-1 synthesis, was useful in reversing early and late acute rejection in clinical trials. Antisense oligonucleotides which interfere with intercellular adhesion molecules which are important in rejection, gave encouraging results in primate renal allografts. The availability of these new drugs will be able to further abate the risk of rejection in organ transplantation. However, caution is warranted with their use in order to avoid the risks of over immunosuppression. Today excellent results can be obtained with the available drugs. Newer immunosuppressive schedules should be designed, not only to reduce the risk of rejection, but also to obtain a better therapeutic index that allows a further improvement of the graft survival while minimising the comorbidity and drug-related toxicity.

AB - Promising immunosuppressive drugs designed to prevent rejection have been developed recently. Two monoclonal antibodies directed against the interleukin-2 (IL-2) receptor, daclizumab and basiliximab, have been shown to significantly reduce the incidence of acute rejection without increasing adverse events. Sirolimus (rapamycin), an agent that inhibits T- and B-response at a later stage than cyclosporin, has been shown to be synergistic with cyclosporin in experimental and clinical studies. Ongoing clinical trials have reported that in renal transplantation high doses of sirolimus are as effective as cyclosporin. SDZ-RAD, a derivative of sirolimus, is also under investigation. FTY-720 another promising drug, prolonged the survival of allografts and synergised with cyclosporin and sirolimus in experimental models. Gusperimus (deoxyspergualin), which inhibits IL-1 synthesis, was useful in reversing early and late acute rejection in clinical trials. Antisense oligonucleotides which interfere with intercellular adhesion molecules which are important in rejection, gave encouraging results in primate renal allografts. The availability of these new drugs will be able to further abate the risk of rejection in organ transplantation. However, caution is warranted with their use in order to avoid the risks of over immunosuppression. Today excellent results can be obtained with the available drugs. Newer immunosuppressive schedules should be designed, not only to reduce the risk of rejection, but also to obtain a better therapeutic index that allows a further improvement of the graft survival while minimising the comorbidity and drug-related toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0032614707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032614707&partnerID=8YFLogxK

M3 - Article

C2 - 10565988

AN - SCOPUS:0032614707

VL - 1

SP - 55

EP - 60

JO - Drugs in R and D

JF - Drugs in R and D

SN - 1174-5886

IS - 1

ER -